# Task C2: Analytical Method, Process Development and Manufacturing for Therapeutics

> **NIH NIH N01** · NANOTHERAPEUTICS, INC. · 2024 · $314,492

## Abstract

The Biopharmaceutical Product Development Services program provides services to facilitate preclinical development of materials that are derived from biotechnology processes, such as monoclonal antibodies and derivatives of monoclonal antibodies; recombinant proteins; peptides; nucleic acid based vectors (siRNA, plasmids); and live, modified-live and/or attenuated entities. Services include: product development planning and evaluation; assay development and product characterization; process development and formulation; GMP manufacturing; and regulatory CMC documentation support. The aim is advance translational research for infectious diseases.

## Key facts

- **NIH application ID:** 11126496
- **Project number:** 272201600006I-P00003-759302300001-1
- **Recipient organization:** NANOTHERAPEUTICS, INC.
- **Principal Investigator:** ISABEL SCHOLZ
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $314,492
- **Award type:** —
- **Project period:** 2023-08-28 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11126496

## Citation

> US National Institutes of Health, RePORTER application 11126496, Task C2: Analytical Method, Process Development and Manufacturing for Therapeutics (272201600006I-P00003-759302300001-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11126496. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*